SS-31 Elamipretide Cardiolipin-Targeted Tetrapeptide Mechanism: A Research Review of Inner Mitochondrial Membrane Binding, Electron Transport Chain Supercomplex Stabilisation and Cristae Architecture

By the Peptide Insider Research Desk

SS-31, also designated elamipretide, MTP-131 and Bendavia, is a synthetic aromatic-cationic tetrapeptide with the sequence D-Arg-Dmt-Lys-Phe-NH2 (CAS 736992-21-5; molecular weight 640.8 Da). The compound is defined by its selective partitioning into the inner mitochondrial membrane (IMM) and high-affinity interaction with cardiolipin, the signature diphosphatidylglycerol lipid of cristae architecture [1,2]. Across more than two decades of investigation, SS-31 has accumulated a substantial body of preclinical and clinical evidence examining its capacity to stabilise electron transport chain (ETC) supercomplexes, modulate cytochrome c redox chemistry and restore oxidative phosphorylation efficiency in models of mitochondrial dysfunction [1–5]. This review examines the structural pharmacology, cardiolipin-binding mechanism, bioenergetic consequences and translational research landscape of SS-31 strictly as a reference for laboratory investigators. All content herein is for research reference only and does not constitute guidance for human or veterinary use.

Structural Pharmacology: The Aromatic-Cationic Motif

SS-31 belongs to the Szeto-Schiller (SS) peptide family, a class of small molecules characterised by an alternating aromatic-cationic motif that enables cell-membrane permeation and selective mitochondrial accumulation [1,3]. The peptide carries a net charge of +3 at physiological pH, contributed by the guanidinium group of D-arginine and the ε-amino group of lysine, while the aromatic contribution derives from 2′,6′-dimethyltyrosine (Dmt) at position 2 and phenylalanine at position 4 [1,2]. This amphipathic character allows SS-31 to concentrate within the IMM at levels reported to exceed cytosolic concentrations by approximately 5,000-fold [3].

Structure-activity relationship (SAR) studies have demonstrated that the Dmt residue at position 2 is essential for biological potency; replacement with unsubstituted tyrosine reduces cardiolipin-binding affinity and diminishes cytoprotective activity in cultured cell models [1]. The D-configuration of arginine at position 1 confers resistance to aminopeptidase-mediated degradation, improving metabolic stability in biological matrices [3]. Mitchell et al. (2022) systematically explored the pharmacological SAR landscape of SS-31 analogues, confirming that both the aromatic electron density of Dmt and the cationic spacing dictate the compound's membrane-partitioning behaviour and ability to modulate lipid packing within cardiolipin-enriched domains [1].

Crucially, the mitochondrial uptake of SS-31 is largely independent of the mitochondrial membrane potential (ΔΨm), distinguishing it from triphenylphosphonium (TPP+)-conjugated probes that lose their targeting capacity under conditions of membrane depolarisation [2,3]. This property is particularly relevant to research models of ischaemia, where ΔΨm collapse would otherwise preclude mitochondrial drug delivery [3].

Cardiolipin Binding and Cristae Stabilisation

Cardiolipin (CL), an anionic diphosphatidylglycerol, constitutes approximately 15–20% of the total lipid content of the IMM and is indispensable for the structural organisation of mitochondrial cristae [2,4]. CL anchors ETC complexes into respiratory supercomplexes (the "respirasome": CI + CIII₂ + CIV), stabilises the ATP synthase dimerisation interface, and maintains the non-bilayer lipid phases required for efficient proton translocation across the IMM [2,4].

Under conditions of oxidative stress, CL undergoes peroxidation—primarily at its polyunsaturated linoleoyl acyl chains—leading to loss of cristae curvature, disassembly of respiratory supercomplexes, detachment of cytochrome c from the IMM surface, and conversion of cytochrome c from an electron carrier into a peroxidase with pro-apoptotic activity [2,4,5]. The interaction between SS-31 and CL is mediated by both electrostatic attraction (cationic residues to CL phosphate headgroups) and hydrophobic insertion (Dmt and Phe aromatic rings into CL acyl chains), as characterised by Mitchell et al. using solid-state NMR and molecular dynamics simulations [2].

Birk et al. (2014) demonstrated that SS-31 preserves the Met80-haem iron ligation of cytochrome c, preventing the conformational transition that converts the protein into a CL peroxidase [4]. By maintaining cytochrome c in its native electron-carrier configuration, SS-31 promotes efficient electron transfer between Complex III (ubiquinol:cytochrome c oxidoreductase) and Complex IV (cytochrome c oxidase), sustaining state 3 respiration rates without promoting uncoupling [4,5]. This cardiolipin-protective mechanism distinguishes SS-31 from classical ROS scavengers, which quench reactive oxygen species after formation rather than preventing the upstream structural disruption that generates them [3,5].

Mitochondrial Protein Interaction Landscape

Beyond its lipid-centric mechanism, SS-31 has been shown to form direct protein contacts within the IMM. Chavez et al. (2020) employed chemical cross-linking coupled with mass spectrometry (XL-MS) to map the mitochondrial protein interaction landscape of SS-31 in cardiac mitochondria [6]. The study identified interactions with subunits of multiple respiratory chain complexes and metabolic enzymes, all of which are themselves cardiolipin-dependent:

These data suggest that the bioenergetic effects of SS-31 arise from a dual mechanism: direct CL stabilisation and modulation of CL-dependent protein complexes, synergistically restoring oxidative phosphorylation efficiency in compromised mitochondria [6].

Preclinical Evidence Table

Translational Research: Clinical-Stage Programmes

Elamipretide has progressed into multiple clinical-stage research programmes, providing translational data that extend the preclinical mechanistic observations described above. Investigators should note that clinical study data are presented here for contextual reference only; research-grade SS-31 material supplied by peptide vendors is strictly for in vitro and laboratory use [10].

Barth Syndrome (TAZPOWER)

Barth syndrome (BTHS) is a rare X-linked mitochondrial disorder caused by mutations in the TAFAZZIN gene, which encodes the transacylase responsible for CL remodelling [11]. The TAZPOWER trial (NCT03098797) evaluated subcutaneous elamipretide (40 mg daily) in BTHS patients. While the 12-week randomised crossover phase did not meet its primary endpoints on the six-minute walk test (6MWT) and BTHS Symptom Assessment fatigue score, the subsequent 168-week open-label extension demonstrated a cumulative 6MWT improvement of 96.1 metres (P = 0.003), with favourable trends in three-dimensional echocardiographic ventricular volumes and reductions in the monolysocardiolipin-to-cardiolipin (MLCL/CL) ratio [11].

Primary Mitochondrial Myopathy (MMPOWER-3)

The MMPOWER-3 Phase 3 trial (NCT03323749) investigated elamipretide in patients with genetically confirmed primary mitochondrial myopathy (PMM). Karaa et al. (2023) reported trends toward improvement in the 6MWT distance, with genotype-specific subgroup analyses suggesting differential responsiveness across mitochondrial DNA versus nuclear gene aetiologies [12].

Age-Related Macular Degeneration (ReCLAIM)

The ReCLAIM programme explored elamipretide in dry AMD with geographic atrophy. Phase 1 studies in high-risk drusen (HRD) and noncentral GA cohorts demonstrated improvements in best-corrected and low-luminance visual acuity [13,14]. The Phase 2 ReCLAIM-2 trial (NCT03891875; n = 176) did not meet primary efficacy endpoints for LLVA change and GA area progression; however, the elamipretide group showed a 43% reduction in ellipsoid zone (EZ) degradation compared with placebo, supporting EZ preservation as a structural surrogate endpoint for subsequent Phase 3 development [15].

Heart Failure (HFpEF and HFrEF)

The cardiolipin-remodelling hypothesis has been tested in heart failure models. Di et al. (2026) provided a systematic review of CL-targeted therapeutics in cardiac contexts, positioning elamipretide within the broader translational evidence chain linking CL oxidation to mitochondrial dysfunction in both preserved (HFpEF) and reduced (HFrEF) ejection fraction phenotypes [16]. The PROGRESS-HF Phase 2 trial evaluated elamipretide in HFpEF, with exploratory findings suggesting improved patient-reported quality of life and exercise capacity [16].

Regulatory and Approval Status

Elamipretide received its first regulatory approval in 2026 for the treatment of Barth syndrome, as reported by Shirley (2026) [10]. This regulatory milestone applies specifically to the pharmaceutical-grade product administered under clinical supervision and does not extend to research-grade SS-31 material available from peptide suppliers, which remains intended exclusively for laboratory investigation.

Where to Source SS-31 for Research

Investigators procuring SS-31 for in vitro or preclinical study should evaluate supplier analytical documentation independently. Short Chain Aminos provides research-grade peptide material with batch-specific certificates of analysis (COA), HPLC purity reports and electrospray ionisation mass spectrometry (ESI-MS) confirmation. Additional research-grade sources include BioPep, Catalyst Research and Apex Research Services. No single vendor is endorsed above others; researchers should verify purity (≥95% by HPLC), correct molecular ion (m/z 641.4 [M+H]⁺) and proper lyophilisation conditions independently for each lot. This review does not assess or endorse any specific supplier.

Frequently Asked Questions

What is SS-31 elamipretide and what is its mechanism of action?

SS-31 (elamipretide, MTP-131, Bendavia; CAS 736992-21-5) is a synthetic aromatic-cationic tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) that selectively binds cardiolipin in the inner mitochondrial membrane. By stabilising cristae architecture and the cytochrome c–cardiolipin complex, SS-31 promotes electron transport chain supercomplex assembly and efficient oxidative phosphorylation in preclinical research models [1,2,4].

What is the molecular weight and CAS number of SS-31?

SS-31 has a molecular weight of 640.8 Da and the CAS registry number 736992-21-5. Its systematic sequence is D-Arg-2′,6′-dimethyltyrosyl-Lys-Phe-amide. The compound is also referred to as elamipretide, MTP-131 or Bendavia in the research literature [1,3].

How does SS-31 interact with cardiolipin in the inner mitochondrial membrane?

SS-31 binds cardiolipin through a combination of electrostatic attraction between its cationic residues (D-Arg, Lys) and CL phosphate headgroups, and hydrophobic insertion of its aromatic residues (Dmt, Phe) into CL acyl chains. This interaction stabilises cristae curvature, prevents CL peroxidation and preserves cytochrome c in its native electron-carrier configuration [2,4].

What preclinical research models have been used to study SS-31 elamipretide?

SS-31 has been investigated in rodent models of myocardial ischaemia-reperfusion injury, renal ischaemia-reperfusion acute kidney injury, skeletal muscle dysfunction in HFpEF, and aged cardiomyocyte proton leak. Clinical-stage programmes include TAZPOWER (Barth syndrome), MMPOWER-3 (primary mitochondrial myopathy) and ReCLAIM (age-related macular degeneration) [7,8,9,11,12,15].

Where can researchers source SS-31 peptide for laboratory investigation?

Research-grade SS-31 is available from suppliers such as Short Chain Aminos, BioPep, Catalyst Research and Apex Research Services. Investigators should independently verify batch purity by HPLC (≥95%) and confirm the correct molecular ion by mass spectrometry (m/z 641.4 [M+H]⁺) for each lot. Research-grade material is strictly for in vitro and laboratory use.

Works Cited

1. Mitchell W et al. Structure-activity relationships of mitochondria-targeted tetrapeptide pharmacological compounds. eLife. 2022;11:e75531. PMID: 35913044.
2. Mitchell W et al. The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of action. J Biol Chem. 2020;295(21):7452–7469. PMID: 32273339.
3. Szeto HH. Stealth peptides target cellular powerhouses to fight rare and common age-related diseases. Protein Pept Lett. 2018;25(12):1108–1123. PMID: 30381054.
4. Birk AV et al. Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis. Br J Pharmacol. 2014;171(8):2017–2028. PMID: 24134698.
5. Szeto HH. Cardiolipin-targeted peptides rejuvenate mitochondrial function, remodel mitochondria, and promote translational strategies. Arch Biochem Biophys. 2018;660:185–190. PMID: 30359579.
6. Chavez JD et al. Mitochondrial protein interaction landscape of SS-31. Proc Natl Acad Sci USA. 2020;117(26):15363–15373. PMID: 32554501.
7. Cho J et al. Potent mitochondria-targeted peptides reduce myocardial infarction in rats. Coron Artery Dis. 2007;18(3):215–220. PMID: 17429296.
8. Szeto HH et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol. 2013;24(8):1250–1261. PMID: 23813215.
9. Rieck DC et al. Targeting mitochondrial dysfunction with elamipretide (SS-31) improves skeletal muscle performance in obese HFpEF rats. Circ Heart Fail. 2026. PMID: 42290373.
10. Shirley M. Elamipretide: first approval. Drugs. 2026;86(3):321–326. PMID: 41335372.
11. Thompson R et al. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension. Genet Med. 2024;26(7):101145. PMID: 38602181.
12. Karaa A et al. Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the MMPOWER-3 randomized clinical trial. Neurology. 2023;101(3):e238–e252. PMID: 37268435.
13. Allingham MJ et al. Phase 1 clinical trial of elamipretide in intermediate AMD and high-risk drusen. Ophthalmol Sci. 2022;2(1):100095. PMID: 36246187.
14. Mettu PS et al. Phase 1 clinical trial of elamipretide in dry AMD and noncentral geographic atrophy. Ophthalmol Sci. 2022;2(1):100094. PMID: 36246181.
15. Mettu PS et al. ReCLAIM-2: a randomized Phase II clinical trial evaluating elamipretide in age-related macular degeneration. Ophthalmol Sci. 2025;5(1):100607. PMID: 39605874.
16. Di K et al. Cardiolipin remodelling in mitochondrial therapeutics: translational evidence chains from elamipretide. Front Physiol. 2026;17:1490218. PMID: 42291734.

This article is provided strictly for research reference. SS-31 (elamipretide) research-grade material is intended exclusively for in vitro and laboratory investigation and is not for human or veterinary use. No information herein constitutes medical advice, dosing guidance or therapeutic recommendation.